Table of Contents

Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes, but has become one of the most talked-about options for weight loss due to its appetite-curbing effects.

About 75% of Americans say they’ve heard of Ozempic and similar medications being used for this purpose. Among those taking GLP-1 drugs, nearly 4 in 10 report using them primarily to lose weight. Still, Ozempic isn’t the only option. If you’re looking for an FDA-approved weight loss medication, several other prescription options are available.

This guide breaks down the best weight loss drugs that work like Ozempic, what results to expect, and who they’re right for.

Key Takeaways

  • Ozempic-like drugs for weight loss, such as Wegovy, Saxenda, and Zepbound, help reduce appetite, increase fullness, and lead to significant, sustained weight loss in both diabetic and non-diabetic patients.
  • Contrave, Qsymia, and Xenical provide non-injectable alternatives. These work through appetite suppression or fat-blocking and may be more accessible for individuals avoiding injections.
  • Regardless of the drug used, combining it with mindful eating, physical activity, and consistent tracking leads to better, longer-lasting results.

Weight Loss Drugs That Work Like Ozempic

When you’re on Ozempic, it’s common to feel less interested in food, which often leads to weight loss. But it isn’t FDA-approved for weight loss. Still, doctors might prescribe it off-label in some cases.

If you’re looking for medications like Ozempic that are specifically indicated for weight loss, here are some options to consider:

Zepbound (tirzepatide)

Zepbound for weight loss, buy zepbound online

Active ingredients: Tirzepatide

Drug class: GIP and GLP-1 receptor agonist

Dosage form and strength: Prefilled, injectable pen and single-dose vial (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)

Dosage frequency: Once weekly

Common side effects: Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and acid reflux

Contraindications:

    • Personal or family history of medullary thyroid carcinoma (MTC)
    • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
    • Hypersensitivity to tirzepatide or any of the components of Zepbound

Pros:

  • Convenience of a once-weekly injection
  • Targets both GIP and GLP-1 receptors
  • Proven to treat moderate to severe obstructive sleep apnea (OSA)
  • Potentially more effective than Ozempic
  • Stronger appetite and craving control

Cons:

  • Higher cost
  • May not be widely available at all pharmacies
  • New Ozempic alternative
  • Higher incidence of gastrointestinal side effects

Zepbound is a relatively new medication for weight management. It gained FDA approval in 2023 and is indicated for adults who have obesity or are overweight with weight-related medical conditions. Zepbound is not yet approved for patients under age 18.

During a 17-month clinical trial, individuals were on a reduced-calorie diet, increased physical activity, and Zepbound. Average weight loss ranged from 34 to 48 lbs for non-diabetic adults and from 28 to 33 lbs for adults with diabetes, compared to 7 lbs for placebo.

Wegovy (semaglutide)

Wegovy (semaglutide), buy Wegovy online

Active ingredients: Semaglutide

Drug class: GLP-1 receptor agonist

Dosage form and strength: Prefilled, injectable pen (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg)

Dosage frequency: Once weekly

Common side effects: Headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, low blood sugar in patients with type 2 diabetes, flatulence, gastroenteritis, GERD, and nasopharyngitis

Contraindications:

    • Personal or family history of medullary thyroid carcinoma (MTC)
    • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
    • Hypersensitivity to semaglutide or any of the components of Wegovy

Pros:

  • Higher dosing than Ozempic
  • Insurance may cover Wegovy for weight loss
  • Once-weekly injection
  • Approved for patients aged 12 years and older
  • Proven to reduce the risk of major adverse cardiovascular events

Cons:

  • More expensive than Ozempic
  • Side effects may be more intense due to the higher dose

Wegovy has shown significant weight-loss benefits in studies. In a 68-week trial, users lost about 33 pounds on average, compared to 6 pounds with placebo. Among those with type 2 diabetes and obesity, Wegovy led to nearly 10% body weight loss versus just 3% in the placebo group.

Saxenda (liraglutide)

Saxenda Pen

Active ingredients: Liraglutide

Drug class: GLP-1 receptor agonist

Dosage form and strength: Prefilled, injectable pen (0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg)

Dosage frequency: Once daily

Common side effects: Nausea, diarrhea, constipation, vomiting, injection site reactions, headache, low blood sugar, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis

Contraindications:

    • Personal or family history of medullary thyroid carcinoma (MTC)
    • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
    • Hypersensitivity to liraglutide or any of the components of Saxenda

Pros:

  • More years of clinical use for obesity
  • Covered by some weight loss programs and insurance plans
  • Higher dosing than Ozempic
  • Approved for patients aged 12 years and older

Cons:

  • Requires daily injections
  • Can be more expensive long-term due to daily use
  • More frequent side effects early on due to daily exposure
  • Shorter duration of action
  • Less effective for weight loss on average

The first major phase 3 trial of Saxenda lasted 20 weeks and was compared to both placebo and orlistat. Across all doses, Saxenda led to significantly greater weight loss than placebo, with average losses ranging from 10.6 to 15.8 pounds depending on the dose.

In a separate 20-week trial with a two-year extension, Saxenda helped participants lose up to 12.8 pounds more than placebo. After two years, those on higher doses maintained an average 17.2-pound weight loss and saw a 15.4% reduction in body fat. Another 56-week study showed that Saxenda users lost an average of 17.6 pounds, compared to 5.7 pounds with placebo. The treatment also improved cardiovascular markers, blood glucose control, and overall quality of life.

Other Alternatives to Ozempic for Weight Loss

Here are more affordable alternatives to Ozempic for weight loss:

Contrave (naltrexone-bupropion)

Contrave (Naltrexone-Bupropion), buy contrave online

Active ingredients: Naltrexone-bupropion

Drug class: Anorexiant, combines an antidepressant (bupropion) and an opioid antagonist (naltrexone)

Dosage form and strength: Extended-release tablets (8 mg naltrexone/90 mg bupropion)

Dosage frequency: Up to 4 tablets per day

Common side effects: Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea

Contraindications:

    • Poorly managed high blood pressure
    • History of seizures or conditions causing seizures
    • Use of other medications with bupropion
    • Ongoing opioid treatment
    • Recent use of monoamine oxidase inhibitors (within 14 days)
    • Hypersensitivity to any of the components of Contrave

Pros:

  • Dual mechanism of action
  • Approved for long-term weight management
  • No risk of dependency or abuse
  • Safer option for individuals with cardiovascular conditions
  • Helps manage cravings and emotional eating
  • Supports better regulation of eating habits

Cons:

  • Requires a gradual dosage increase over four weeks
  • Only available as a brand-name drug
  • Not FDA-approved for use in people younger than 18 years old

Bupropion curbs appetite and boosts metabolism by raising certain brain chemicals. But over time, your body can produce a signal that weakens this effect. Naltrexone blocks that signal, helping bupropion keep working to support weight loss.

In a real-world setting, people taking Contrave lost an average of 9.2% of their body weight within six months and 9.7% after a year, showing significantly better outcomes than those in the control group.

A systematic review also emphasized how this drug pair targets not just physical weight, but also psychological contributors to obesity. It showed promise in reducing behaviors like emotional or binge eating.

One particular study followed individuals with moderate to severe binge eating symptoms. By week 4, many began to notice improvements. At 24 weeks, 83% of participants reported minimal or no binge eating episodes. These changes were accompanied by better self-regulation, meaningful weight loss, improved mood, and even reductions in depression-related symptoms.

Xenical (orlistat)

Xenical (Orlistat) for weight loss, orlistat pill

Active ingredients: Orlistat

Drug class: Lipase inhibitor

Dosage form and strength: Capsules (120 mg)

Dosage frequency: Taken 3 times a day

Common side effects: Oily spotting, passing gas with oily or greasy residue, sudden need to go to the bathroom, fatty/oily stool, needing to go to the bathroom more often, and trouble controlling bowel movements

Contraindications:

    • Pregnancy
    • Should not be used if the body cannot properly absorb nutrients
    • Individuals with liver-related bile flow problems
    • Hypersensitivity to any of the components of Xenical

Pros:

  • Available as a generic
  • Non-stimulant mechanism
  • No risk of dependency
  • Offers additional cardiovascular benefits
  • Safer option for individuals with cardiovascular risks
  • Approved for obese pediatric patients aged 12 years and older

Cons:

  • Causes unpleasant side effects
  • Must follow a low-fat diet to minimize side effects
  • May reduce the absorption of vitamins that dissolve in fat
  • Does not address behavioral or psychological factors like cravings or emotional eating

Orlistat stops the body from absorbing some of the fat you eat. It blocks digestive enzymes responsible for breaking down fat, so about 30% of that fat passes through your system without being digested.

In a 24-week trial, people taking orlistat lost an average of 10.2 pounds. They also saw greater improvements in BMI and waist size compared to those on placebo, losing nearly 2 inches off their waistlines.

During one clinical trial for Xenical, users lost 11% of their body weight in the first year and kept off 6.9% over four years. They were also less likely to develop type 2 diabetes than those not taking the drug. In another study focused on people with type 2 diabetes, orlistat helped lower HbA1c levels after a year. It also led to more weight loss, 3.89% compared to just 1.27% in the placebo group.

Qsymia (phentermine-topiramate)

Qsymia Bottles

Active ingredients: Phentermine-topiramate

Drug class: Anorexiant, combines a stimulant (phentermine) and an anticonvulsant (topiramate)

Dosage form and strength: Extended-release capsules (3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg, 15 mg/92 mg)

Dosage frequency: Once daily

Common side effects: Tingling or numbness, dizziness, altered taste, insomnia, constipation, dry mouth, depression, joint pain, fever, flu, and stretched or torn ligament.

Contraindications:

    • Pregnancy due to possible birth defects, such as clefts in the baby’s mouth or face
    • People with hyperthyroidism or glaucoma
    • Individuals who have used monoamine oxidase inhibitors in the past 14 days
    • Hypersensitivity to any of the components of Qsymia

Pros:

  • Combination therapy leading to greater efficacy
  • The addition of topiramate may lower the risk of tolerance
  • Approved for obese pediatric patients aged 12 years and older

Cons:

  • Requires titration (dose adjustment) to find the optimal dose
  • Schedule IV controlled substance

Qsymia combines phentermine and topiramate to help with weight loss. Phentermine curbs hunger by triggering brain chemicals that suppress appetite. Topiramate increases feelings of fullness, reduces cravings, and can even make some foods taste less appealing.

In a 20-week study, this combination led to a 4.1% drop in body weight, compared to 3.6% with phentermine alone. A meta-analysis also found phentermine-topiramate to be one of the most effective weight-loss drugs, with 75% of users losing at least 5% of their body weight. On average, people taking it lost 19.4 pounds over a year.

Tips for Safer & Effective Results While on Medications Similar to Ozempic

Here are some strategies you can apply day-to-day:

  • Start low and increase gradually

    When taking medications like Ozempic, Wegovy, or Zepbound, the initial dose is intentionally small to help your body adjust and reduce side effects like nausea, bloating, or fatigue. Jumping straight to a higher dose may increase the risk of unpleasant or even serious reactions.
      • Expect each dose to last at least 4 weeks before any increase. This is standard for GLP-1 medications.
      • Note when side effects worsen or improve to help your doctor tweak your treatment schedule.
      • If side effects become difficult to manage, ask your doctor about holding your dose steady for longer before increasing.

  • Track your progress consistently

    Monitoring your weight loss journey helps you stay motivated and catch potential plateaus early. It’s also a way to see results beyond the number on the scale.
      • Weigh yourself once a week at the same time of day, ideally in the morning before eating.
      • Take progress photos every 2 to 4 weeks, wearing the same clothing to visualize changes in body shape.
      • Use a notebook or app like MyFitnessPal, Lose It!, or Fitbit to log meals, emotions, energy levels, and side effects.

  • Practice mindful and balanced eating

    No medication can completely override a diet high in sugar, processed foods, or excess calories. Medications like GLP-1 agonists lower appetite, but what you choose to eat still matters.
      • Focus on high-protein meals to preserve muscle during weight loss (e.g., eggs, fish, tofu, chicken).
      • Include fiber-rich foods like berries, beans, oats, and leafy greens to support digestion and help with fullness.
      • Avoid high-fat, greasy meals, as these can worsen medication side effects like diarrhea.
      • Use smaller plates to help control portions. Most people need less food while on weight-loss meds.
      • If you’re not hungry, don’t force yourself to eat, but also avoid skipping essential nutrients.

  • Stay physically active

    Exercise enhances the effects of weight loss medications and improves mental health, blood sugar control, and sleep. You don’t need to hit the gym every day, consistent movement matters more than intensity.
      • Aim for at least 150 minutes of moderate activity per week.
      • Take short walking breaks after meals to aid digestion and blood sugar regulation.
      • Try low-impact exercises like swimming, cycling, yoga, or bodyweight workouts if joint pain is an issue.
      • Set reminders to stand or stretch if you sit for long hours. Every bit of movement helps.
      • Use a fitness tracker to stay accountable, or join a step challenge with friends for motivation.

  • Follow up regularly with your healthcare provider

    Regular check-ins ensure you’re losing weight safely, adjusting doses correctly, and staying ahead of potential issues like nutrient deficiencies or severe side effects.
      • Schedule follow-ups every 4-12 weeks, depending on your doctor’s advice and how you’re responding to treatment.
      • Bring a list of symptoms or concerns to your appointment.
      • Ask about labs that may be needed, such as thyroid function (especially with GLP-1s), blood sugar levels, kidney function, and cholesterol.
      • If you’re on multiple medications (for blood pressure, diabetes, etc.), make sure your doctor adjusts them as you lose weight to avoid overtreatment.
      • Consider speaking with a dietitian or weight-loss specialist for added support and meal planning.

Final Thoughts

Drugs such as Zepbound, Wegovy, and Saxenda use similar GLP-1-based mechanisms to reduce appetite and support long-term weight loss. Others like Contrave, Qsymia, and Xenical work differently but still offer meaningful results.

Each option has its pros, side effects, and dosing differences. Some are weekly injections, others are daily pills. What they all share is the potential to support weight loss when combined with a healthy diet, regular activity, and medical supervision. These Ozempic alternatives for weight loss can be just as effective, depending on your needs.

Frequently Asked Questions

Trulicity and Ozempic are not the same, although both are GLP-1 receptor agonists used to manage type 2 diabetes. They contain different active ingredients. Trulicity has dulaglutide, while Ozempic contains semaglutide.

Wegovy typically results in more weight loss than Ozempic because it’s approved at a higher semaglutide dose specifically for weight management. Ozempic is mainly prescribed for diabetes but may be used off-label for weight loss.

Yes, many patients transition from Ozempic to Wegovy under a doctor’s supervision to achieve greater weight loss. Since both drugs contain semaglutide, switching may involve dose adjustments.

Zepbound (tirzepatide) is currently considered one of the most effective injectable medications for weight loss, showing greater results than semaglutide in clinical trials.

Studies suggest that Mounjaro (tirzepatide) leads to more weight loss and better blood sugar control than Ozempic, but individual response may vary.

In the first month, some people may lose around 5 to 10 pounds on Mounjaro, though results depend on dosage, diet, and activity level.

Rybelsus is the tablet form of semaglutide, the same active ingredient in Ozempic, and can support weight loss, though it’s primarily approved for type 2 diabetes.

Zepbound, a newer GLP-1/GIP dual agonist, is gaining attention as a next-generation alternative to Ozempic for weight loss.

Wegovy generally costs more because it’s FDA-approved for weight loss and prescribed at higher doses of semaglutide than Ozempic, which is approved for diabetes.

Phentermine-topiramate (Qsymia) is among the most potent FDA-approved oral medications for weight loss, showing significant results when used with lifestyle changes.

Related Articles

Sources

Nadeem, R., & Nadeem, R. (2025, May 7). How Americans view Weight-Loss drugs and their potential impact on obesity in the U.S. Pew Research Center. https://www.pewresearch.org/science/2024/02/26/how-americans-view-weight-loss-drugs-and-their-potential-impact-on-obesity-in-the-u-s/

Montero, A., Sparks, G., Presiado, M., & Hamel, L. (2024, May 10). KFF Health Tracking poll May 2024: The public’s use and views of GLP-1 drugs | KFF. KFF. https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183

Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/s0140-6736(21)00213-0

Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., Rössner, S., Savolainen, M. J., & Van Gaal, L. (2011). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity, 36(6), 843–854. https://doi.org/10.1038/ijo.2011.158

Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443–1451. https://doi.org/10.1038/ijo.2013.120

Lui, D. T. W., Tsoi, K. H., Fong, C. H. Y., Jiang, N. S., Chow, W. S., & Yuen, M. M. A. (2024). Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience. Endocrine. https://doi.org/10.1007/s12020-024-04029-2

Kulak-Bejda, A., Bejda, G., & Waszkiewicz, N. (2020). Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review. Archives of Medical Science, 17(4), 940–953. https://doi.org/10.5114/aoms.2020.96908

Guerdjikova, A. I., Walsh, B., Shan, K., Halseth, A. E., Dunayevich, E., & McElroy, S. L. (2017). Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. Advances in Therapy, 34(10), 2307–2315. https://doi.org/10.1007/s12325-017-0613-9

Moini, J., Ahangari, R., Miller, C., & Samsam, M. (2020). Obesity therapy. In Elsevier eBooks (pp. 387–410). https://doi.org/10.1016/b978-0-12-819751-6.00017-7

Jain, S., Ramanand, S., Ramanand, J., Akat, P., Patwardhan, M., & Joshi, S. (2011). Evaluation of efficacy and safety of orlistat in obese patients. Indian Journal of Endocrinology and Metabolism, 15(2), 99. https://doi.org/10.4103/2230-8210.81938

Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjo?Stro?M, L. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002). Clinical efficacy of orlistat therapy in overweight and obese patients with Insulin-Treated Type 2 Diabetes. Diabetes Care, 25(6), 1033–1041. https://doi.org/10.2337/diacare.25.6.1033

Grabarczyk, T. R. (2017). Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 38(1), 19–28. https://doi.org/10.1002/phar.2048

Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016). Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA, 315(22), 2424. https://doi.org/10.1001/jama.2016.7602